Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas.

In the nab -P + Gem arm, ORR by RECIST was significantly better for patients who experienced a metabolic response compared with patients who did not; the effects on progression-free survival (PFS) and OS did not reach statistical significance ( P = 0.110 and 0.464, respectively; Table 1 ).

also in 111,027 other papers